Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. - Wikidata - wikimedia - TriplyDB

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

http://www.wikidata.org/entity/Q51743176

about

Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Paraproteinemic neuropathy: a practical review Autoimmune neuromuscular disorders Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy Pathogenesis and treatment of immune-mediated neuropathies.Practical considerations on the use of rituximab in autoimmune neurological disorders Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.Chronic dysimmune neuropathies: Beyond chronic demyelinating polyradiculoneuropathy.Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.Effect of stem cell transplantation for B-cell malignancies on disease course of associated polyneuropathy.Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Immunotherapy in Peripheral Neuropathies Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Molecularly targeted therapies for dysimmune neuropathies The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.Evidence-based treatment of chronic immune-mediated neuropathies.Treatment in inflammatory neuropathies.Neuropathy and paraproteins: review of a complex association.Novel treatment for immune neuropathies on the horizon.An update on monoclonal gammopathy and neuropathy.Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.Multifocal motor neuropathy: current therapies and novel strategies.Monoclonal antibodies in neuroinflammatory diseases.Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.Acquired neuropathies.Progress in peripheral nerve disease research in the last two years.Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.IgM MGUS associated with anti-MAG neuropathy: a single institution experience.Outcome measures in neuromuscular disease: is the world still flat?

P2860

Q24197877-027BEE5B-A595-448D-9EE4-A499DB7F0EA7 Q24201954-2CBF3E4D-0E8A-40DF-8D2E-92D9C41D2880 Q24236599-01415668-D81A-4B77-B92D-634AF3E50917 Q26773047-CF619534-57A1-4FE3-99A7-72828A167086 Q28261039-05026214-8475-45A5-8E40-A344FA3580C7 Q28264405-997D660A-100A-4F4B-9B02-6AC13D8907EE Q28390264-1926DD3A-A5BA-452C-AE1C-FA0DB7518021 Q30234567-A1443C36-7EE7-4850-B8A2-E79916F2EAB9 Q30397454-CF93239D-5170-4C05-AA6D-582AE9F354CD Q33695919-AA1B296B-F261-40B1-811D-696719FA3329 Q34106817-EFE4F5E9-CDB3-44B1-9AC1-3D3E4ED0F36E Q34344264-8EFED502-B02C-4043-8C2C-A30D2E702698 Q34409385-0733C39E-3E8C-4A60-BF79-2C6296D7645C Q34409447-9DA263A1-A260-4575-AF9E-6588BCDF1194 Q34555067-89FAAF03-B9AC-44C0-B97C-87F291B917E1 Q35089149-9CE96463-66ED-4915-9066-1C67630942A9 Q35121614-4AC390D7-58A4-4CBA-9B89-BBAE2EEDBD78 Q35544312-9104ADF7-929E-4D38-A9D1-C5B160A4A6B1 Q35625820-89CEE097-BD49-477C-9E7C-4D569EC814A6 Q35858046-CBD86C11-6B31-4121-8152-F520C820251B Q36297853-AA22662B-C63D-41A2-BB07-C9723756D830 Q36365583-FF24D776-94E5-4270-9710-FAE2EB5D9685 Q36484418-5ED66801-9221-49A0-B45F-1CB7E597E774 Q36484465-11A404FD-FF64-451F-B147-6FA6EC713024 Q37254545-43CCE045-AB38-4F98-BB32-7DB7DA40C455 Q37381546-34C56778-9733-4CCE-AD7D-F7900C65DEDF Q37550515-842E9590-FCE6-4E13-817C-1054A2B9C406 Q37733512-DBC12CA5-2196-496C-865E-FACEAAAF051D Q37854873-2BA6C47B-4339-4B2E-82AE-0E9EBF2D0A0C Q37892641-F574BB7F-094A-4D7C-8AEF-80F8C3B4B1A2 Q37957050-C2A0E316-DB06-43D6-972D-A78231FAD1A1 Q38006761-6792F610-A7D1-49C6-9260-396F56292421 Q38091664-529AE364-D377-4ABF-99D3-F61290E3BB6C Q38092121-2BF9F6EB-AA2D-4094-B130-9E0ACCC3F801 Q38114487-8E8C81AB-365D-49D4-8B00-6C79EEDD4ADA Q38114834-A136812F-89A6-4D23-81D3-FA84BE8B87A5 Q38155072-20D4C2AE-96B4-4E5F-A517-6BB23553C6BC Q38208249-A77A3834-9B52-45B1-B2E3-AC61DCF14F5E Q38311759-08A72A53-9D2E-4023-924D-C8BB32E3884A Q38538591-0639D65D-6B45-4059-9CEA-A222B6C20278

P2860

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

http://www.wikidata.org/entity/Q51743176

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@en

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@nl

type

label

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@en

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@nl

prefLabel

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@en

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@nl

P1433

Q51743176-55A2EBBD-CD53-4382-8988-999062CF40F0

P1476

Q51743176-A1FE9C7C-B57E-478D-9874-9F101D1224A9

P2093

Q51743176-1F0D9427-CDFA-4C8C-A447-174AEF4AC86F

Q51743176-4A248605-ED0A-4220-9193-A9932F64D8FB

Q51743176-9E901D15-5A2B-470D-983A-FFC88090D2B7

Q51743176-B50CA8CA-6983-4940-B496-01E8A12B2C60

Q51743176-C8A84E28-9101-440E-8EE1-83BEBB81515C

Q51743176-F28C60FE-5377-427B-82DA-243D4CB49C70

Q51743176-F7BB2403-A7F2-4D8D-8BE0-5DBD30B24D23

P304

Q51743176-2FC6A331-18AE-4433-A9AA-C148BE6B3169

P31

Q51743176-12D95FCF-0ED1-4B12-9E47-68523B8C20E8

P356

Q51743176-7C3BBC33-79B6-4004-88BA-11CD83C63B38

P433

Q51743176-DDF060D5-138B-4B71-B3C4-E75F3BD1BD4D

P478

Q51743176-798DC591-284D-4E80-A481-72C0CA9465E6

P577

Q51743176-B6A5824F-8798-4C06-B0BB-641FA850AB69

P698

Q51743176-81AED921-27DD-404B-9C02-8880028A85A2

P921

Q51743176-29644E98-A3BA-42CD-B2E9-40D0FD65BA94

Q51743176-6E1AD5D6-F32A-4584-8FB3-9452F0C7810B

P356

P1433

Annals of Neurology

P1476

Placebo-controlled trial of ri ...... body demyelinating neuropathy.

@en

P2093

Angelika F Hahn

http://www.w3.org/2001/XMLSchema#string

Beverly McElroy

http://www.w3.org/2001/XMLSchema#string

Goran Rakocevic

http://www.w3.org/2001/XMLSchema#string

James M Dambrosia

http://www.w3.org/2001/XMLSchema#string

Marinos C Dalakas

http://www.w3.org/2001/XMLSchema#string

Mohammad Salajegheh

http://www.w3.org/2001/XMLSchema#string

Raghavan Raju

http://www.w3.org/2001/XMLSchema#string

P304

286-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.21577

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19334068

http://www.w3.org/2001/XMLSchema#string

P921